In this issue:
Talazoparib prolongs survival in advanced disease
Exemestane vs tamoxifen in premenopausal breast cancer
21-gene expression assay guides use of chemotherapy
Crizotinib prolongs survival in ALK+ NSCLC
Nivolumab + ipilimumab in NSCLC; TMB validated as a biomarker
Nivolumab promising in pretreated advanced NSCLC
Lung cancer data from NZ’s Midland Cancer Network region
RET fusions in advanced colorectal cancers
First-line FOLFOXIRI + bevacizumab for right-sided mCRC?
Age affects oxaliplatin efficacy in perioperative treatment of rectal cancer
Please login below to download this issue (PDF)